Fintech PR
MEDSiS Officially Announces Publication of White Paper and Has Plans to Enter 2020 With More Than 34 Countries on Their Financial Ecosystem
On the eve of MEDSiS International’s publishing of its White Paper, the budding FinTech payments company that prides themselves on strengthening currencies for countries and financial freedom for everyone else, is promising several new announcements over the coming days. This includes new banking and issuing agreements, banking territories around the world, and much more. “Our goal has been not only to get our current contracts in place, but to create a global environment that will support those contracts, especially in Argentina and Brazil,” comments Joshua Dax Cabrera, CEO of MEDSiS.
Due to earlier funding challenges, MEDSiS has been delayed in the launching of their over 15 million user contracts in Argentina and Brazil, but as 2019 comes to a close, completion in these areas and goals are ramping up.
With the launch of their White Paper, the commitment to complete their partnerships that would allow them to issue to consumers in more than 34 countries globally, and their updated plans for both their legacy payments platforms as well as Maxwell, MEDSiS is on the verge of reaching their publicly stated 2019 goals. With new partnerships being finalized this week, even the licensing and previous profit projections will be outdated as MEDSiS expects to move to a minimum of 160 basis points on transactions for all live contracts, which would make MEDSiS and the future Maxwell ecosystem even more lucrative.
MEDSiS latest blitz to close out the year seems to be the largest and most ambitious yet. But with both announced, and unannounced funding partners, it looks like the emerging payments company has a few final surprises for the market before the end of the year.
SOURCE MEDSiS
Fintech PR
Sweat Economy Brings Japanese Language Capabilities to Sweat Wallet
The move enables millions of native Japanese speakers to access the app seamlessly
LONDON, March 19, 2024 /PRNewswire/ — Sweat Economy, the Web3 ecosystem on a mission to make the world more physically active, has launched a Japanese-language version of its Sweat Wallet mobile app. The move paves the way for millions of Japanese users to interact with the Sweat Economy ecosystem in their native tongue.
Japan has been one of the primary focus markets for Sweat Economy due to its strong and active fitness community. Sweat Wallet makes fitness fun and rewarding by allowing users to earn $SWEAT with their steps. Users can then trade $SWEAT for other mainstream crypto such as USDT, participate in prize draws, or transfer their earnings to other crypto platforms. Since launching in September 2022, Sweat Wallet has gained over 213,000 users in Japan, who have minted over 78 million $SWEAT and logged nearly 200 million steps.
Oleg Fomenko, Co-Founder of Sweat Economy said: “We’re thrilled to launch Sweat Wallet in native Japanese, in what is one of the largest fitness markets in the world. Japan has always been one of our primary focus markets. Our Japanese community members on Discord have been very active and passionate about our product development. We are super excited to launch a localized version of the app to help Japanese users navigate and experience the app without any language barrier. We aim to inspire a new wave of physical activity in the country and incentivize individuals to lead healthier lives, paving the way for the next billion users looking to participate in The Movement Economy.”
The Japanese version of Sweat Wallet is now available for download on iOS and Android. In addition to the Japanese launch, Sweat Economy has engineered a major breakthrough with NEAR Protocol’s Chain Abstraction technology—with Oleg Fomenko delivering a demo of the milestone at ETHDenver. It demonstrates that the Sweat Wallet will soon be able to allow its 15 million users to run transactions on chains other than NEAR, without the need for complex knowledge to operate on different chains. This development demonstrates Sweat Economy’s commitment to onboarding millions into both Web3 and The Movement Economy.
Oleg Fomenko, co-founder of Sweat Economy is available for interviews.
About Sweat Economy
Sweat Economy is a Web3 ecosystem on a mission to help the world be more physically active by incentivizing activity. It is powered by $SWEAT or Sweat Token, a crypto asset representing tokenized physical activity, minted by steps. The token is managed via the Sweat Wallet dApp, the non-custodial Web3 mobile wallet dApp for managing your $SWEAT and other crypto holdings. Sweat Wallet is a top 5 dApp globally, designed for the crypto-curious. Sweat Wallet is one of the world’s most popular Dapps, boasting over 3.7 million monthly unique active wallets on the platform. The Wallet works in tandem with the Sweatcoin app to accurately track users’ steps and distance and rewards them with $SWEAT that can be spent on fitness gear, athletic apparel, and other products. Sweat Wallet also fosters community and competition through its multiple gamified features, such as Sweat Hero—the dynamic NFT game based on your steps. With over 140M+ registered Sweatcoin users, and more than 10 million Sweat Token holders, Sweat Economy is facilitating one of the most significant onboardings in Web3 history.
View original content:https://www.prnewswire.co.uk/news-releases/sweat-economy-brings-japanese-language-capabilities-to-sweat-wallet-302089534.html
Fintech PR
Nereus Unveils Revolutionary On-Chain Derivatives Trading Platform on Polygon Network
HONG KONG, March 18, 2024 /PRNewswire/ — Today, Nereus is excited to announce the launch of its cutting-edge derivatives trading platform on the Polygon network. Led by a team of DeFi experts, Nereus aims to transform the way people trade by offering advanced features and a commitment to pushing the boundaries of DeFi.
Highlights of the Nereus Platform:
- Isolated Margin: Tailored control over trade size and exposure.
- Up to 70x Leverage: Amplify trading potential with minimal spread and zero price impact.
- Blazing Speed: Over 5,000 transactions per second and sub-10ms exchange latency.
- Gasless Experience: Seamless trading without the burden of gas fees.
- Cross-Chain Deposits: Simplify deposits and withdrawals across various chains.
Nereus provides a platform that combines the best aspects of centralized and decentralized exchanges, making trading more secure and transparent. This launch marks a significant step forward for derivatives trading, offering a more accessible and efficient option for investors worldwide.
By embracing innovation and leveraging the Polygon network, Nereus is leading the way towards a more inclusive and decentralized trading environment. The company’s goal is to make trading accessible to everyone, regardless of their background or location.
In the near future, Nereus plans to enhance its platform with a proprietary ZK-powered Layer 2 solution, utilizing Polygon’s Chain Development Kit (CDK). This move is aimed at improving the platform’s performance and user experience, demonstrating our commitment to innovation.
Nereus has recently been added to COCA’s DApps portfolio, expanding its reach to more users.
About Nereus
A leader in the DeFi space, Nereus is dedicated to delivering innovative trading solutions that combine speed, security, and leverage, all built on the robust Polygon network.
Discover the future of trading with Nereus at https://nereus.finance
Photo – https://mma.prnewswire.com/media/2362088/Nereus_Finance.jpg
Logo – https://mma.prnewswire.com/media/2365558/Nereus_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/nereus-unveils-revolutionary-on-chain-derivatives-trading-platform-on-polygon-network-302092120.html
Fintech PR
QDOSE® Platform Partnership for Personalised Dosimetry in Radiopharmaceutical Therapy
MELBOURNE, Australia and DRESDEN, Germany, March 18, 2024 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an agreement to commercially partner the QDOSE® dosimetry software platform with ABX-CRO Advanced Pharmaceutical Services Forschungsgesellschaft mbH (ABX-CRO), a full-service contract research organisation (CRO) based in Dresden, and its development partner, Stockholm-based Quantinm AB.
QDOSE® is a validated, versatile software platform that enables reliable estimation of patient-specific dosimetry for both therapeutic and diagnostic radiopharmaceuticals. Telix intends to integrate the QDOSE® platform into its therapeutic radiopharmaceutical programs and clinical collaborations to enable the development of personalised treatment regimens. Personalised radiopharmaceutical therapy administration based on individual patient dosimetry has the potential to improve clinical outcomes by optimising treatment response while reducing effects on normal healthy organs and optimising the use of isotope supply chains.
QDOSE® supports dosimetry calculations using planar imaging, tomographic imaging, single/multi time point imaging and hybrid combinations. QDOSE® incorporates additional tools for attenuation and background correction. The QDOSE® platform will be integrated with Telix’s artificial intelligence (AI) products as an accessible tool for clinicians and third-party commercial drug developers. QDOSE® has received 510(k) clearance from the United States Food and Drug Administration (FDA) and is Conformité Européenne (CE) marked for clinical use within the European Union (EU).
Dr Christian Behrenbruch, Managing Director and Group CEO of Telix said, “In nuclear medicine, dosimetry analysis is used to calculate the absorbed dose of radiation received by different parts of the body. Rapid, reliable and personalised dosimetry is becoming an increasingly important future direction of cancer care and regulatory authorities now expect to see dosimetry analysis. QDOSE® has an excellent performance track record and we are committed to positioning QDOSE® as a new industry standard in dosimetry analysis.”
The arms’ length up-front transaction consideration is non-material. Telix will pay undisclosed product royalties and fees on product sales.
About Telix Pharmaceuticals Limited
Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals and associated medical devices. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX).
Visit www.telixpharma.com for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on X and LinkedIn.
Telix’s lead imaging product, gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the FDA,[1] by the Australian Therapeutic Goods Administration (TGA),[2] and by Health Canada.[3] Telix’s miniaturised surgical gamma probe, SENSEI®, for minimally invasive and robotic-assisted surgery, has attained a marketing authorisation in the U.S., having been registered with the FDA and has attained a CE Mark for use in the European Economic Area for the intra-operative detection of sentinel lymph nodes. With the exception of Illuccix® and SENSEI® as noted above, no Telix product has received a marketing authorisation in any jurisdiction.
Telix Investor Relations
Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: [email protected]
Legal Notices
The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. The information contained in this announcement is subject to change without notification.
This announcement may contain forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “outlook”, “forecast” and “guidance”, or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on the Company’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect the Company’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical studies, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialisation of Telix’s product candidates, if or when they have been approved; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the ASX or on our website.
To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to publicly update or revise any forward-looking statements contained in this announcement, whether as a result of new information, future developments or a change in expectations or assumptions.
©2024 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals, Illuccix® and SENSEI® names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.
[1] Telix ASX disclosure 20 December 2021. |
[2] Telix ASX disclosure 2 November 2021. |
[3] Telix ASX disclosure 14 October 2022. |
Logo – https://mma.prnewswire.com/media/1920208/4598441/Telix_Main_Logo_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/qdose-platform-partnership-for-personalised-dosimetry-in-radiopharmaceutical-therapy-302092075.html
-
Fintech PR6 days ago
Request Finance Acquires Consola Finance To Become the Ultimate Enterprise Finance Platform for Both Crypto and Fiat
-
Fintech PR6 days ago
OPTRUST FULLY FUNDED FOR 15TH CONSECUTIVE YEAR
-
Fintech PR6 days ago
Artmarket.com: Artprice looks at 2023’s NFT auction market, and the 50 most successful digital artists, a promising future with the record for cryptocurrencies in ETFs on Wall Street
-
Fintech PR6 days ago
Europe’s Secret Weapon In Its Energy War With Russia
-
Fintech PR6 days ago
Aegros Limited proposes to issue debentures in a series of tranches up to an aggregate face value of AUD25 million for subscription by investors
-
Fintech PR6 days ago
CGTN AMERICA & CCTV UN: Global Media Dialogue: Why 2024 is the year to “Spring into China?”
-
Fintech PR6 days ago
G42 Develops BoardNavigator to Reimagine Boardroom Dynamics
-
Fintech PR7 days ago
Bybit Web3 Partners with Kamino Finance to Open up Access to Solana Ecosystem and dAPPs